Harry L.A. Janssen - Concepedia

Author

Harry L.A. Janssen

Also Known As

DeVole, Nata, Elina Hyppönen, H JANSSEN, H Janssen, H L A Janssen, H L Janssen, H. Janssen, H. L. A. JANSSEN, H. L. A. Janssen, H. L. Janssen

729

Publications

47.5K

Citations

106

H-Index

179

Concepts

All Affiliations

Erasmus MC University Health Network University of Toronto Erasmus University Rotterdam Toronto General Hospital

About

Harry L.A. Janssen is an author at Erasmus MC specializing in medicine, viral hepatitis, and hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	61	140	19.6K
2	Public Health	12	12	708
3	Health Sciences	8	8	1.1K
4	Allergy	2	2	249
5	Engineering	1	1	12

Harry L.A. Janssen

348

Publications

39.4K

Citations

H-Index

Page 1

	Year	Citations
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Pietro Lampertico, Kosh Agarwal, Thomas Berg, Journal of Hepatology Hepatitis DViral HepatitisHepatitis BHepatitisAntiviral Therapy	2017	5.3K
Treatment of HCV Infection by Targeting MicroRNA Harry L.A. Janssen, Hendrik W. Reesink, Eric Lawitz, New England Journal of Medicine	2013	2.2K
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, JAMA	2012	1.5K
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Harry L.A. Janssen, Monika van Zonneveld, Hakan Şentürk, The Lancet HepatologyInterferon Alfa-2b AloneViral HepatitisRandomised TrialImmunology	2005	1.2K
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis Bart J. Veldt, E. Jenny Heathcote, Heiner Wedemeyer, Annals of Internal Medicine	2007	600
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity Ton Lisman, T.N. Bongers, Jelle Adelmeijer, Hepatology	2006	595
Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan, The Lancet. Gastroenterology & hepatology HepatologyViral HepatitisHepatitis BHepatitisAntiviral Therapy	2016	535
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy George Papatheodoridis, George Ν. Dalekos, Vana Sypsa, Journal of Hepatology Hepatitis DHepatologyViral HepatitisMedicineHepatitis B	2015	518
Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection†‡ Jeroen N. Stoop, Renate G. van der Molen, Carla C. Baan, Hepatology	2005	506
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver Felix E. de Jongh, Harry L.A. Janssen, Robert A. de Man, Gastroenterology HepatologyViral HepatitisLiver PhysiologyPrognostic IndicatorsImmunology	1992	424

Page 1